These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 11834971)

  • 21. Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
    Bellman PC
    AIDS; 1998 Jul; 12(11):1333-40. PubMed ID: 9708413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.
    Burger D; Hugen P; Reiss P; Gyssens I; Schneider M; Kroon F; Schreij G; Brinkman K; Richter C; Prins J; Aarnoutse R; Lange J;
    AIDS; 2003 May; 17(8):1157-65. PubMed ID: 12819517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients failing saquinavir therapy require an early change to indinavir before HIV-1 viral load reaches high levels.
    Dronda F; Pérez-Elías MJ; Antela A; Casado JL; Martí-Belda P; Cobo J
    Antivir Ther; 1999; 4(2):117-21. PubMed ID: 10682157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests.
    Vora S; Michon C; Junet C; Balavoine JF; Renold-Moynier C; Yerly S; Perrin L
    AIDS; 2000 Dec; 14(17):2795-7. PubMed ID: 11125903
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
    Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
    AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.
    Danel C; Moh R; Peytavin G; Anzian A; Minga A; Gomis OB; Seri B; Nzunettu G; Gabillard D; Salamon R; Bissagnene E; Anglaret X
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):62-6. PubMed ID: 17263634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
    Carr A; Chuah J; Hudson J; French M; Hoy J; Law M; Sayer D; Emery S; Cooper DA
    AIDS; 2000 Jun; 14(9):1171-80. PubMed ID: 10894281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Papillary necrosis associated with the HIV protease inhibitor indinavir.
    Dieleman JP; van der Feltz M; Bangma CH; Stricker BH; van der Ende ME
    Infection; 2001 Aug; 29(4):232-3. PubMed ID: 11545487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
    Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
    AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virologic response associated with a change in protease inhibitor therapy.
    Butcher D; Greene J; Duong P; Markson L
    Arch Intern Med; 2000 Feb; 160(3):394-5. PubMed ID: 10668845
    [No Abstract]   [Full Text] [Related]  

  • 32. High rebound of plasma and cellular HIV load after discontinuation of triple combination therapy.
    Jubault V; Burgard M; Le Corfec E; Costagliola D; Rouzioux C; Viard JP
    AIDS; 1998 Dec; 12(17):2358-9. PubMed ID: 9863885
    [No Abstract]   [Full Text] [Related]  

  • 33. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
    Gray CM; Schapiro JM; Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor.
    Grabar S; Pradier C; Le Corfec E; Lancar R; Allavena C; Bentata M; Berlureau P; Dupont C; Fabbro-Peray P; Poizot-Martin I; Costagliola D
    AIDS; 2000 Jan; 14(2):141-9. PubMed ID: 10708284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.
    Kemper CA; Witt MD; Keiser PH; Dubé MP; Forthal DN; Leibowitz M; Smith DS; Rigby A; Hellmann NS; Lie YS; Leedom J; Richman D; McCutchan JA; Haubrich R;
    AIDS; 2001 Mar; 15(5):609-15. PubMed ID: 11316998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paronychia in association with indinavir treatment.
    Colson AE; Sax PE; Keller MJ; Turk BK; Pettus PT; Platt R; Choo PW
    Clin Infect Dis; 2001 Jan; 32(1):140-3. PubMed ID: 11118393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
    Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
    AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects.
    Bongiovanni M; Bini T; Chiesa E; Cicconi P; Adorni F; Monforte d'Arminio A
    Antiviral Res; 2004 Apr; 62(1):53-6. PubMed ID: 15026202
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 6-base pair insertion in the protease gene of HIV type 1 detected in a protease inhibitor-naive patient is not associated with indinavir treatment failure.
    Stürmer M; Staszewski S; Doerr HW; Hertogs K
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):967-8. PubMed ID: 14678603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.